Legend Biotech (LEGN) Projected to Release Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of $0.0563 per share and revenue of $355.9630 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. The company had revenue of $305.10 million for the quarter, compared to analysts’ expectations of $306.51 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 56.5% compared to the same quarter last year. On average, analysts expect Legend Biotech to post $-0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Legend Biotech Trading Up 0.5%

NASDAQ LEGN traded up $0.09 during trading on Tuesday, hitting $19.10. The company had a trading volume of 1,175,605 shares, compared to its average volume of 2,497,735. Legend Biotech has a one year low of $16.24 and a one year high of $39.16. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -28.12 and a beta of 0.37. The company’s fifty day moving average is $27.77 and its 200-day moving average is $23.24.

Insider Buying and Selling

In other news, CEO Ying Huang sold 5,566 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the sale, the chief executive officer owned 241,872 shares in the company, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LEGN. Suvretta Capital Management LLC boosted its stake in Legend Biotech by 73.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock worth $143,672,000 after acquiring an additional 2,790,620 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Legend Biotech by 120.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock valued at $47,274,000 after purchasing an additional 1,188,449 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Legend Biotech by 4.6% during the third quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock valued at $53,251,000 after purchasing an additional 72,371 shares in the last quarter. State Street Corp lifted its holdings in shares of Legend Biotech by 31.0% during the fourth quarter. State Street Corp now owns 1,516,368 shares of the company’s stock valued at $32,966,000 after purchasing an additional 359,246 shares during the last quarter. Finally, Davern Capital Partners LP purchased a new position in shares of Legend Biotech during the fourth quarter valued at approximately $22,972,000. 70.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LEGN shares. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of Legend Biotech in a research note on Tuesday, July 28th. UBS Group reissued a “neutral” rating and issued a $28.00 price target (down from $49.00) on shares of Legend Biotech in a research note on Monday, July 27th. Benchmark restated a “buy” rating on shares of Legend Biotech in a report on Tuesday, July 28th. Morgan Stanley cut their price objective on Legend Biotech from $49.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, TD Cowen upped their target price on Legend Biotech to $29.00 and gave the stock a “hold” rating in a report on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $55.29.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.